Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.
Calidi's losses got bigger this quarter—they lost $2.94 per share instead of $1.99 last year. When a company's losses grow, it means they're spending more money than they're making, which is something to watch as you think about whether the company is getting closer to profitability or moving further away.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.